• argenx posted 2Q 2026 profit of $472 million, swinging from $245 million a year earlier; operating profit rose 146% year over year to $494 million.
• Product net sales climbed 60% year over year to $1.52 billion, rising 17% from 1Q; 1H net sales rose to $2.81 billion.
• R&D expenses increased to $486 million; SG&A costs rose to $417 million, reflecting VYVGART franchise commercialization and pipeline investment.
• Expanded the U.S. label for VYVGART and VYVGART Hytrulo to all adult gMG serotypes, including triple seronegative patients.
• Kept key readouts on track, with ALKIVIA myositis results due in 3Q26 and EMPASSION MMN data for empasiprubart expected in 4Q26.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. arGEN-X SE published the original content used to generate this news brief on July 23, 2026, and is solely responsible for the information contained therein.